Pacific Biosciences of California, Inc.
PACB
$1.33
$0.064.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 160.01M | 154.58M | 156.11M | 152.36M | 154.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.01M | 154.58M | 156.11M | 152.36M | 154.01M |
| Cost of Revenue | 117.55M | 108.61M | 113.09M | 114.67M | 110.74M |
| Gross Profit | 42.45M | 45.97M | 43.02M | 37.69M | 43.27M |
| SG&A Expenses | 143.19M | 163.48M | 176.13M | 185.83M | 189.42M |
| Depreciation & Amortization | 369.44M | 375.27M | 381.10M | 386.94M | 27.40M |
| Other Operating Expenses | 8.25M | 5.07M | 5.07M | 5.07M | 998.00K |
| Total Operating Expenses | 736.33M | 760.23M | 785.86M | 818.92M | 469.38M |
| Operating Income | -576.33M | -605.64M | -629.75M | -666.57M | -315.36M |
| Income Before Tax | -546.06M | -503.20M | -526.31M | -657.73M | -309.54M |
| Income Tax Expenses | 318.00K | 432.00K | 49.00K | 14.00K | 316.00K |
| Earnings from Continuing Operations | -546.38 | -503.63 | -526.36 | -657.75 | -309.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -546.38M | -503.63M | -526.36M | -657.75M | -309.85M |
| EBIT | -576.33M | -605.64M | -629.75M | -666.57M | -315.36M |
| EBITDA | -193.89M | -217.27M | -233.81M | -263.95M | -274.18M |
| EPS Basic | -1.84 | -1.69 | -1.79 | -2.29 | -1.14 |
| Normalized Basic EPS | -1.19 | -1.27 | -1.33 | -1.43 | -0.71 |
| EPS Diluted | -1.84 | -1.70 | -1.79 | -2.29 | -1.14 |
| Normalized Diluted EPS | -1.19 | -1.26 | -1.31 | -1.41 | -0.69 |
| Average Basic Shares Outstanding | 1.20B | 1.18B | 1.15B | 1.13B | 1.10B |
| Average Diluted Shares Outstanding | 1.20B | 1.20B | 1.18B | 1.15B | 1.12B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |